http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
-
Eyegate Pharma (EYEG) Highlights Positive Results in Second PRK Study
-
Eyegate Pharma (EYEG) Reports Positive Results in Punctate Epitheliopathy Study
-
EyeGate Pharma Announces Positive Results in Second PRK Study
-
EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy Study
-
EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy Study
-
EyeGate Pharma Announces Positive Results in Second PRK Study
-
EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care
-
EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care
-
EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules
-
EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules
-
EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies
-
EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies
-
Eyegate Pharma (EYEG) Reports Randomization of First Patients in Study for Punctate Epitheliopathies
-
Eyegate Pharma (EYEG) Reports Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis
-
EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies
-
EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies
-
EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis
-
EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis
-
EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference
-
EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference
-
Eyegate Pharma (EYEG) Reports First Patient Enrollment in PRK Pilot Study
-
EyeGate Announces Enrollment of First Patient in PRK Pilot Study
-
EyeGate Announces Enrollment of First Patient in PRK Pilot Study
-
Eyegate Pharma (EYEG) Appoints Peter Greenleaf to Board
-
EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf
-
EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf
-
EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
-
EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
-
Eyegate Pharma (EYEG) Granted FDA Approval of Two IDE Submissions for Ocular Bandage Gel
-
EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gel
-
EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gel
-
Eyegate Pharma (EYEG) Says it Addressed Final FDA Action Item with Submission of IDE Amendment for Ocular Bandage Gel
-
EyeGate Addresses Final FDA Action Item with Submission of IDE Amendment for Ocular Bandage Gel
-
EyeGate Addresses Final FDA Action Item with Submission of IDE Amendment for Ocular Bandage Gel
-
EyeGate Files Supplement to Investigational Device Exemption to Commence Study in Punctate Epitheliopathy using the EyeGate Ocular Bandage Gel
-
EyeGate Files Supplement to Investigational Device Exemption to Commence Study in Punctate Epitheliopathy using the EyeGate Ocular Bandage Gel
-
Eyegate Pharma (EYEG) Responds to FDA Review, Addressing 3 of 4 Action Items in Second Amendment with Submission of Investigational Device Exemption
-
EyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel
-
EyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel
-
EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd
-
EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd
-
EyeGate Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
-
EyeGate Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
-
Eyegate Pharma (EYEG) Secures New Patent for Iontophoretic Contact Lens Technology
-
EyeGate Issued New Patent for Iontophoretic Contact Lens Technology
-
Eyegate Pharma (EYEG) Announces FDA Feedback on IDE Amendment for Second Pilot Study of Ocular Bandage Gel
-
EyeGate Receives FDA Feedback on Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel
-
UPDATE: Eyegate Pharma (EYEG) Secures Milestone Payment for Complete Enrollment of Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior
-
EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis

